Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.19, beating the estimate of USD -0.36.

EBIT: As of FY2026 Q1, the actual value is USD -2.046 M.

Brainstorm Cell Therapeutics Inc. announced its financial results for the quarter ended March 31, 2026, through a press release issued on May 15, 2026, which was furnished as Exhibit 99.1 to a Form 8-K report. Specific financial and operational metrics, as well as any outlook or guidance, are not detailed within the provided Form 8-K filing itself, however, the following information was included in the reference .

Financial Performance (Three Months Ended March 31, 2026)

• Cash, cash equivalents, and restricted cash were approximately $0.2 million as of March 31, 2026, compared to approximately $0.3 million as of December 31, 2025 .
• Research and development expenditures, net, were approximately $0.8 million, a decrease from approximately $1.3 million for the three months ended March 31, 2025 .
• General and administrative expenses were approximately $1.3 million, down from approximately $1.8 million for the three months ended March 31, 2025 .
• Net loss for the three months ended March 31, 2026, was approximately - $2.1 million, an improvement from a net loss of approximately - $2.9 million for the three months ended March 31, 2025 .
• Operating loss was - $2,046 thousand, compared to - $3,089 thousand for the same period in 2025 .
• Financial income (expense), net, was - $81 thousand, compared to $46 thousand for the same period in 2025 .
• The change in fair value of warrant liability was $0, compared to $179 thousand for the same period in 2025 .

Balance Sheet Highlights (As of March 31, 2026)

• Cash and cash equivalents were $15 thousand, down from $29 thousand as of December 31, 2025 .
• Total current assets were $184 thousand, compared to $307 thousand as of December 31, 2025 .
• Total assets were $755 thousand, decreasing from $1,022 thousand as of December 31, 2025 .
• Total current liabilities were $11,764 thousand, an increase from $11,007 thousand as of December 31, 2025 .
• Total liabilities were $11,764 thousand, up from $11,007 thousand as of December 31, 2025 .
• Total stockholders’ deficit was - $11,009 thousand, compared to - $9,985 thousand as of December 31, 2025 .

Corporate Financing

• In February 2026, Brainstorm Cell Therapeutics Inc. secured a total of $2 million in funding through two strategic private placement agreements, each consisting of stock and warrants .

Outlook / Guidance

Brainstorm Cell Therapeutics Inc. is focused on completing the final steps to initiate its planned Phase 3 ENDURANCE study of NurOwn in ALS, with ongoing progress in site activation, manufacturing readiness, and regulatory engagement. The company anticipates that successful completion of Part A of the study will generate the clinical data required to support a new Biologics License Application (BLA) submission for NurOwn. The initiation of the enrollment phase is contingent upon securing the necessary financing .